Wei Chen

6687847, Feb 3, 2004

Apr 19, 2000

09/552136

Marcos K. Aguilera - Bures-sur-Yvette, FR
Wei Chen - Nashua NH
Sam Toueg - Ithaca NY

Cornell Research Foundation, Inc. - Ithaca NY

H02H 305

714 4, 714 47, 714 23, 714 15

New failure detector mechanisms particularly suitable for use in asynchronous distributed computing systems in which processes may crash and recover, and two crash-recovery consensus mechanisms, one requiring stable storage and the other not requiring it. Both consensus mechanisms tolerate link failures and are particularly efficient in the common runs with no failures or failure detector mistakes. Consensus is achieved in such runs within 3 time and with 4n messages, where is the maximum message delay and n is the number of processes in the system.

6890717, May 10, 2005

Nov 28, 2000

09/724304

Yi-Ping Li - Brookline MA, US
Wei Chen - Brookline MA, US

Forsyth Dental Infirmary for Children - Boston MA

C12Q001/68

435 6, 435 681, 435 691, 435440, 536 231, 536 241

The invention provides nucleic acid molecules derived from human osteoblasts. The nucleic acid molecules are used in applications such as diagnostic methods, screening assays and as hybridization probes and primers.

7435830, Oct 14, 2008

Mar 2, 2005

11/071880

Andrew M. K. Pennell - San Francisco CA, US
James B. Aggen - Burlingame CA, US
J. J. Kim Wright - Redwood City CA, US
Subhabrata Sen - Bangalore Karnataka, IN
Wei Chen - Fremont CA, US
Daniel Joseph Dairaghi - Palo Alto CA, US
Penglie Zhang - Foster City CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 487/04

548453

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

7435831, Oct 14, 2008

Sep 1, 2005

11/219637

Wei Chen - Fremont CA, US
Penglie Zhang - Foster City CA, US
James B. Aggen - Burlingame CA, US
Daniel Joseph Dairaghi - Palo Alto CA, US
Andrew M. K. Pennell - San Francisco CA, US
Subhabrata Sen - Bangalore Karnataka, IN
J. J. Kim Wright - Redwood City CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 487/04

548453

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

7462325, Dec 9, 2008

Nov 30, 2001

09/997999

Lawrence F. Hancock - North Andover MA, US
Robert Deans - Grafton MA, US
Wei Chen - Stillwater OK, US

Nomadics, Inc. - Stillwater OK

B32B 5/02

422 8205, 526285, 25230135, 422 8208

This invention involves a series of articles, dispersions, compositions, methods, and kits. Several aspects of the invention involve dispersed particles made from polymers having a delocalized π-orbital backbone structure, as well as methods for making and using such particles. The delocalized π-orbital backbone allows the polymer to have a high degree of luminosity, useful in many embodiments of the invention. The polymers of this invention can also have bulky substituents to prevent intermolecular π-π interactions that can decrease luminosity. The polymer may also have charged side chains immobilized relative to the backbone, which can allow the polymer to be made into stably suspended micro- or nanoparticles dispersed in solution, sometimes with very narrow size distributions. In some embodiments, depending on the conditions used to synthesize and prepare the particles, the particles each consist of a single polymer molecule. Side groups, including biological, biochemical, or chemical molecules, can be attached to the polymer to provide additional functions, such as altering the luminosity of the polymer, or allowing the polymer to bind to certain molecules, such as in a chemical sensor or in a biological assay.

7486851, Feb 3, 2009

Apr 27, 2005

11/115531

Di Yang - Fremont CA, US
Giovanni Barbarossa - Saratoga CA, US
Wei Chen - Fremont CA, US

Avanex Corporation - Fremont CA

G02B 6/00

385 27

One embodiment of the present invention includes a plurality of first optical elements and a second optical element optically coupled to one another in cascaded fashion. Each first optical element has a group delay response characterized by a first period such that only one group delay peak occurs within a first channel. By contrast, the second optical element has a group delay response characterized by a second period, which is less than the first period, such that more than one group delay peak occurs within the first channel. The preferred embodiment uses cascaded GT etalons to provide the desired group delay responses. One advantage of the present invention is that the passband of the dispersion compensator is increased relative to prior art designs without increasing insertion losses. Alternatively, the same passband common in prior art designs may be achieved with fewer GT etalons, thereby reducing insertion losses.

7519240, Apr 14, 2009

Jul 17, 2007

11/779108

Brent E. Little - Glen Head NY, US
Wei Chen - Ellicott City MD, US

Infinera Corporation - Sunnyvale CA

G02F 1/01

385 1, 385 2, 385 3, 385 4, 385 8, 385 9, 385 11, 385 14, 385 15, 385 27, 385 31, 385 45, 385 46

A wavelength independent multi-section optical coupler having at least three optical couplers, and at least two differential phase cells. Each optical coupler has two waveguides forming a coupling region having a net coupling value. The coupling value for each coupling region of the at least three optical couplers is different than the coupling values of the other two coupling regions. Each differential phase cell connects adjacent ones of said optical couplers. Each differential phase cell causes a differential phase shift in light signals traversing between the optical couplers, wherein the differential phase shifts of the differential phase cells, and the coupling value for each coupling region are chosen so as to minimize wavelength, and fabrication sensitivity of said wavelength independent multi-section optical coupler for a designed power splitting ratio.

7524845, Apr 28, 2009

Jun 22, 2006

11/474132

Penglie Zhang - Foster City CA, US
Andrew M. K. Pennell - San Francisco CA, US
John J. Kim Wright - Redwood City CA, US
Wei Chen - Fremont CA, US
Manmohan R. Leleti - Sunnyvale CA, US
Yandong Li - San Jose CA, US
Lianfa Li - Palo Alto CA, US
Yuan Xu - Fremont CA, US

ChemoCentryx, Inc. - Mountain View CA

A61K 31/5377
A61K 31/496
C07D 471/04
C07D 487/04

5142358, 51425304, 514248, 514249, 5142621, 544121, 544362, 544236, 544262, 544350

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.